Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Phase 3 Uveitis Program Locked and Loaded

Canaccord Genuity reiterates a 'Hold' on XOMA, Ltd. (NASDAQ: XOMA) price target of $2.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on gevokizumab potential in noninfectious uveitis and cardiovascular. Phase 2a and Phase 2b CRP reduction data suggest 052’s promise in CV. Early clinical data indicates 052’s potential benefit in Behcet’s and non-infectious uveitis, but final pivotal trial design will be critical for success."

For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.

Shares of XOMA, Ltd. closed at $2.62 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Cummins (CMI) PT Lowered to $675 at Jefferies
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project